Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer.

Abstract:

:Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival (OS), progression-free survival (PFS) and platinum-free interval (PFI). Results:ABCG2 rs3219191D>I, UGT1A rs10929302G>A and UGT1A rs2741045T>C polymorphisms were significantly associated with all three parameters (OS, PFS and PFI) and were used to generate a score. Patients in high-risk group had a poorer OS (hazard ratio [HR]: 1.8; 95% CI: 1.3-2.7; p = 0.0019), PFS (HR: 2.0; 95% CI: 1.4-2.9; p < 0.0001) and PFI (HR: 1.9; 95% CI: 1.4-2.8; p = 0.0002) compared with those in low-risk group. Conclusion: The prognostic-score including polymorphisms involved in drug and estrogen pathways stratifies OCP according to OS, PFS and PFI.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Gagno S,Bartoletti M,Romualdi C,Poletto E,Scalone S,Sorio R,Zanchetta M,De Mattia E,Roncato R,Cecchin E,Giorda G,Toffoli G

doi

10.2217/pgs-2020-0049

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

995-1010

issue

14

eissn

1462-2416

issn

1744-8042

journal_volume

21

pub_type

杂志文章
  • Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.

    abstract:AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0046

    authors: Liu N,Irvin MR,Zhi D,Patki A,Beasley TM,Nickerson DA,Hill CE,Chen J,Kimmel SE,Limdi NA

    更新日期:2017-07-01 00:00:00

  • Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine.

    abstract::Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.62

    authors: Frueh FW

    更新日期:2009-07-01 00:00:00

  • Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran.

    abstract::High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0058

    authors: Aghabozorg Afjeh SS,Shams J,Hamednia S,Boshehri B,Olfat A,Omrani MD

    更新日期:2020-09-01 00:00:00

  • Genetic variation in statin intolerance and a possible protective role for UGT1A1.

    abstract::The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0146

    authors: V Willrich MA,Kaleta EJ,Bryant SC,Spears GM,Train LJ,Peterson SE,Lennon VA,Kopecky SL,Baudhuin LM

    更新日期:2018-01-01 00:00:00

  • Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.

    abstract::While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.1

    authors: Narasimhan S,Lohoff FW

    更新日期:2012-03-01 00:00:00

  • Clinical consequences of ADRbeta2 polymorphisms.

    abstract::The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.3.349

    authors: Hawkins GA,Weiss ST,Bleecker ER

    更新日期:2008-03-01 00:00:00

  • Clinical pharmacogenetics: how do we ensure a favorable future for patients?

    abstract::Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0192

    authors: Wiltshire T,Dong OM

    更新日期:2018-04-01 00:00:00

  • Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.

    abstract:AIM:To investigate the pharmacokinetics of voriconazole when administered to HIV-positive patients receiving treatment with atazanavir-containing therapies according to CYP2C19 genotype. MATERIALS & METHODS:We describe four HIV-positive patients with pulmonary aspergillosis treated with voriconazole and atazanavir-bas...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.92

    authors: Calcagno A,Baietto L,Pagani N,Simiele M,Audagnotto S,D'Avolio A,De Rosa FG,Di Perri G,Bonora S

    更新日期:2014-07-01 00:00:00

  • Mapping translational research in personalized therapeutics: from molecular markers to health policy.

    abstract::Translational research is frequently used in the bioscience literature to refer to the translation of basic science into practical applications at the point of patient care. With the introduction of theragnostics, a new medical subspecialty that fuses therapeutics and diagnostic medicine with the goal of providing ind...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.2.177

    authors: Ozdemir V,Williams-Jones B,Cooper DM,Someya T,Godard B

    更新日期:2007-02-01 00:00:00

  • Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.

    abstract::Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS). OCT alleles were investigated in PCOS patients to identify genetic 'bad responders' and 'nonresponders' to metformin including their possible effects on glucose metabolism without treatment. We genotyped eight SNPs in OCT1, OCT2...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.223

    authors: Schweighofer N,Lerchbaum E,Trummer O,Schwetz V,Pieber T,Obermayer-Pietsch B

    更新日期:2014-02-01 00:00:00

  • Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

    abstract::Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究

    doi:10.1517/phgs.5.2.203.27481

    authors: Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

    更新日期:2004-03-01 00:00:00

  • The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series.

    abstract::High-throughput data collection using gene microarrays has great potential as a method for addressing the pharmacogenomics of complex biological systems. Similarly, mechanism-based pharmacokinetic/pharmacodynamic modeling provides a tool for formulating quantitative testable hypotheses concerning the responses of comp...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.5.525

    authors: Almon RR,DuBois DC,Piel WH,Jusko WJ

    更新日期:2004-07-01 00:00:00

  • Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.

    abstract:AIMS:To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). MATERIALS & METHODS:This was a multicenter prospective study. One hundred and forty four pa...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2217/pgs.12.53

    authors: Tian J,Qin X,Fang K,Chen Q,Hou J,Li J,Yu W,Chen D,Hu Y,Li X

    更新日期:2012-05-01 00:00:00

  • Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.

    abstract:AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.17

    authors: Blum S,Vardi M,Brown JB,Russell A,Milman U,Shapira C,Levy NS,Miller-Lotan R,Asleh R,Levy AP

    更新日期:2010-05-01 00:00:00

  • Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.

    abstract:BACKGROUND & METHODS:Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,随机对照试验

    doi:10.2217/pgs.14.167

    authors: Mitropoulou C,Fragoulakis V,Bozina N,Vozikis A,Supe S,Bozina T,Poljakovic Z,van Schaik RH,Patrinos GP

    更新日期:2015-01-01 00:00:00

  • Drug-induced liver injury: insights from genetic studies.

    abstract::Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.111

    authors: Andrade RJ,Robles M,Ulzurrun E,Lucena MI

    更新日期:2009-09-01 00:00:00

  • Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.

    abstract:OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.12.1705

    authors: Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

    更新日期:2007-12-01 00:00:00

  • History repeats itself: the family medication history and pharmacogenomics.

    abstract::Related to many drug gene-product interactions, application of pharmacogenomics can lead to improved medication efficacy while decreasing or avoiding adverse drug reactions. However, utilizing pharmacogenomics without other information does not allow for optimal medication therapy. Currently, there is a lack of docume...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2015-0015

    authors: Smith TR,Kearney E,Hulick PJ,Kisor DF

    更新日期:2016-05-01 00:00:00

  • VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence.

    abstract::Aim: To determine if selected serotonergic and noradrenergic gene variants are associated with heroin addiction. Subjects & methods: A total of 126 variants in 19 genes in subjects with Dutch European ancestry from The Netherlands. Subjects included 281 opioid-dependent volunteers in methadone maintenance or heroin-as...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0137

    authors: Randesi M,van den Brink W,Levran O,Blanken P,van Ree JM,Ott J,Kreek MJ

    更新日期:2019-04-01 00:00:00

  • Psychiatric pharmacists' perception on the use of pharmacogenomic testing in the mental health population.

    abstract:AIM:Pharmacogenomics could play a role in improving patient care, reducing adverse drug reactions and overall healthcare costs. However, whether it is utilized may be determined by how it is perceived by healthcare professionals, including pharmacists. METHODS:A cross-sectional web-based survey evaluated psychiatric p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.22

    authors: Shishko I,Almeida K,Silvia RJ,Tataronis GR

    更新日期:2015-01-01 00:00:00

  • Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation.

    abstract::The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.2.3.203

    authors: Huang S

    更新日期:2001-08-01 00:00:00

  • Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

    abstract::Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranuloc...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2018-0188

    authors: Legge SE,Walters JT

    更新日期:2019-03-01 00:00:00

  • Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy.

    abstract::Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

    journal_title:Pharmacogenomics

    pub_type: 评论,杂志文章

    doi:10.2217/14622416.8.9.1267

    authors: Yanow SK,Purcell LA,Lee M,Spithill TW

    更新日期:2007-09-01 00:00:00

  • Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.

    abstract::Pharmacogenomics (PGx) implementation in clinical practice is steadily increasing. PGx uses genetic information to personalize medication use, which increases medication efficacy and decreases side effects. The availability of clinical PGx guidelines is essential for its implementation in clinical settings. Currently,...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0056

    authors: Nagy M,Attya M,Patrinos GP

    更新日期:2020-11-01 00:00:00

  • Pharmacogenomics of episodic migraine: time has come for a step forward.

    abstract::Migraine is characterized by heterogeneous behavior in response to drugs. Many resources have been invested in attempting to unravel the genetic basis of migraine, while the role of genetics in responses to currently available drugs has received less attention. We performed a systematic literature search identifying o...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.20

    authors: Viana M,Terrazzino S,Genazzani AA,Grieco GS,Cargnin S,Santorelli FM,Pierelli F,Tassorelli C,Nappi G,Di Lorenzo C

    更新日期:2014-03-01 00:00:00

  • Pharmacogenetic aspects in treatment of colorectal cancer--an update.

    abstract::Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.6.767.22825

    authors: Stoehlmacher J,Goekkurt E,Lenz HJ

    更新日期:2003-11-01 00:00:00

  • Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin.

    abstract::A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

    journal_title:Pharmacogenomics

    pub_type: 评论,信件

    doi:10.2217/pgs.12.151

    authors: Botton MR,Hutz MH,Suarez-Kurtz G

    更新日期:2012-11-01 00:00:00

  • Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.

    abstract:AIMS:Carvedilol is an effective treatment in hypertension and chronic heart failure. The medical impact of polymorphisms in CYP2D6 and in the β-adrenergic receptors ADRB1 and ADRB2 on the pharmacokinetics and pharmacodynamics of carvedilol is controversial. METHODS:After carvedilol 25 mg was administered to 110 volunt...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章

    doi:10.2217/pgs.11.20

    authors: Sehrt D,Meineke I,Tzvetkov M,Gültepe S,Brockmöller J

    更新日期:2011-06-01 00:00:00

  • Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets.

    abstract:AIM:Pharmacogenetic landscapes of commonly used antiplatelet drugs, warfarin and clopidogrel have been studied in-depth in many countries. However, there is a paucity of data to understand their patterns in the Arab populations. MATERIALS & METHODS:We analyzed the whole exome sequencing datasets of 100 Qatar individua...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0130

    authors: Sivadas A,Sharma P,Scaria V

    更新日期:2016-11-01 00:00:00

  • Genetics of antipsychotic-induced weight gain: update and current perspectives.

    abstract::Antipsychotic medications are used to effectively treat various symptoms for different psychiatric conditions. Unfortunately, antipsychotic-induced weight gain (AIWG) is a common side effect that frequently results in obesity and secondary medical conditions. Twin and sibling studies have indicated that genetic factor...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.13.207

    authors: Kao AC,Müller DJ

    更新日期:2013-12-01 00:00:00